{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:28:43Z","timestamp":1793046523601,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.jacl.2017.11.006","type":"journal-article","created":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T22:16:47Z","timestamp":1511302607000},"page":"62-69.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins"],"prefix":"10.1016","volume":"12","author":[{"given":"Yukiko","family":"Hasegawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5459-6984","authenticated-orcid":false,"given":"Mika","family":"Hori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Nakagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariko","family":"Harada-Shiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuko","family":"Uchigata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2017.11.006_bib1","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.atherosclerosis.2011.01.021","article-title":"Diabetes and the risk of coronary heart disease in the general Japanese population: the Japan Public Health Center-based prospective (JPHC) study","volume":"216","author":"Saito","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2017.11.006_bib2","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/bmj.316.7134.823","article-title":"Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)","volume":"316","author":"Turner","year":"1998","journal-title":"BMJ"},{"key":"10.1016\/j.jacl.2017.11.006_bib3","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1210\/jc.2011-0622","article-title":"Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: subanalysis of the Japan Diabetes Complications Study (JDCS)","volume":"96","author":"Sone","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jacl.2017.11.006_bib4","doi-asserted-by":"crossref","first-page":"8416","DOI":"10.1074\/jbc.275.12.8416","volume":"275","author":"Taghibiglou","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jacl.2017.11.006_bib5","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1007\/s00125-006-0177-8","article-title":"Messenger RNA levels of genes involved in dysregulation of postprandial lipoproteins in type 2 diabetes: the role of Niemann-Pick C1-like 1, ATP-binding cassette, transporters G5 and G8, and of microsomal triglyceride transfer protein","volume":"49","author":"Lally","year":"2006","journal-title":"Diabetologia"},{"issue":"Suppl 1","key":"10.1016\/j.jacl.2017.11.006_bib6","first-page":"S11","article-title":"Standards of medical care in diabetes\u20142011","volume":"34","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2017.11.006_bib7","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0021-9150(86)90175-9","article-title":"Influence of endogenous hyperinsulinism on high density lipoprotein2 level in type 2 (non-insulin-dependent) diabetes mellitus and impaired glucose tolerance","volume":"60","author":"Jiao","year":"1986","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2017.11.006_bib8","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"Suppl 3","key":"10.1016\/j.jacl.2017.11.006_bib9","doi-asserted-by":"crossref","first-page":"S434","DOI":"10.2337\/diabetes.51.2007.S434","article-title":"The multiple actions of GP-1 on the process of glucose-stimulated insulin secretion","volume":"51","author":"MacDonald","year":"2002","journal-title":"Diabetes"},{"key":"10.1016\/j.jacl.2017.11.006_bib10","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/0006-291X(90)92041-W","article-title":"Suppression of synthesis and release of glucagon by glucagon-like peptide-1 (7-36 amide) without affect on mRNA level in isolated rat islets","volume":"167","author":"Yamato","year":"1990","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jacl.2017.11.006_bib11","doi-asserted-by":"crossref","first-page":"444","DOI":"10.4158\/EP.13.5.444","article-title":"Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin","volume":"13","author":"Viswanathan","year":"2007","journal-title":"Endocr Pract"},{"key":"10.1016\/j.jacl.2017.11.006_bib12","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1185\/030079908X253870","article-title":"Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years","volume":"24","author":"Klonoff","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.jacl.2017.11.006_bib13","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.2337\/dc09-2062","article-title":"Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database","volume":"33","author":"Horton","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2017.11.006_bib14","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.atherosclerosis.2010.05.028","article-title":"Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus","volume":"212","author":"Schwartz","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2017.11.006_bib15","doi-asserted-by":"crossref","first-page":"G943","DOI":"10.1152\/ajpgi.00303.2004","article-title":"GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats","volume":"288","author":"Qin","year":"2005","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jacl.2017.11.006_bib16","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jhep.2010.09.032","article-title":"Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase","volume":"54","author":"Ben-Shlomo","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jacl.2017.11.006_bib17","doi-asserted-by":"crossref","first-page":"e49152","DOI":"10.1371\/journal.pone.0049152","article-title":"GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-leiden mice","volume":"7","author":"Parlevliet","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jacl.2017.11.006_bib18","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.molmet.2014.09.005","article-title":"GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance","volume":"3","author":"Taher","year":"2014","journal-title":"Mol Metab"},{"key":"10.1016\/j.jacl.2017.11.006_bib19","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/hep.21006","article-title":"Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob\/ob mice","volume":"43","author":"Ding","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jacl.2017.11.006_bib20","doi-asserted-by":"crossref","first-page":"e31394","DOI":"10.1371\/journal.pone.0031394","article-title":"Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL\/6J mice","volume":"7","author":"Lee","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jacl.2017.11.006_bib21","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/hep.23569","article-title":"Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in\u00a0vitro by modulating elements of the insulin signaling pathway","volume":"51","author":"Gupta","year":"2010","journal-title":"Hepatology"},{"issue":"Suppl 1","key":"10.1016\/j.jacl.2017.11.006_bib22","first-page":"S49","article-title":"8. Cardiovascular disease and risk management","volume":"38","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jacl.2017.11.006_bib23","doi-asserted-by":"crossref","first-page":"667","DOI":"10.5551\/jat.4143","article-title":"Impact of statin treatment on the clinical fate of heterozygous familial hypercholesterolemia","volume":"17","author":"Harada-Shiba","year":"2010","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jacl.2017.11.006_bib24","article-title":"Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovacular Diseases 2017","year":"2017","journal-title":"Jpn Atheroscler Soc"},{"key":"10.1016\/j.jacl.2017.11.006_bib25","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s13340-015-0223-1","article-title":"A large-scale, observational study to investigate the current status of diabetes complications and their prevention in Japan: research outline and baseline data for type 2 diabetes\u2014JDCP Study 1","volume":"6","author":"Tajima","year":"2015","journal-title":"Diabetol Int"},{"key":"10.1016\/j.jacl.2017.11.006_bib26","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(08)61246-5","article-title":"Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial","volume":"373","author":"Garber","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2017.11.006_bib27","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.diabres.2008.03.018","article-title":"Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes","volume":"81","author":"Seino","year":"2008","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jacl.2017.11.006_bib28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2017.11.006_bib29","doi-asserted-by":"crossref","first-page":"517","DOI":"10.5551\/jat.15792","article-title":"Executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan\u20142012 version","volume":"20","author":"Teramoto","year":"2013","journal-title":"J Atheroscler Thromb"},{"key":"10.1016\/j.jacl.2017.11.006_bib30","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1001\/archinte.161.11.1413","article-title":"Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality","volume":"161","author":"Cui","year":"2001","journal-title":"Arch Intern Med"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287417305160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287417305160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:33:23Z","timestamp":1761831203000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287417305160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S1933287417305160"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2017.11.006","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2017.11.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 National Lipid Association. All rights reserved.","name":"copyright","label":"Copyright"}]}}